Amgen Inc

Amgen Inc Stock Forecast & Price Prediction

Live Amgen Inc Stock (AMGN) Price
$277.63

32

Ratings

  • Buy 14
  • Hold 16
  • Sell 2
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$277.63

P/E Ratio

34.86

Volume Traded Today

$3.2M

Dividend

$2.25

52 Week High/low

346.85/257.80

Amgen Inc Market Cap

$146.52B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $AMGN ๐Ÿ›‘

Before you buy AMGN you'll want to see this list of ten stocks that have huge potential. Want to see if AMGN made the cut? Enter your email below

AMGN Summary

Based on ratings from 32 stock analysts, the Amgen Inc stock price is expected to increase by 18.28% in 12 months. This is calculated by using the average 12-month stock price forecast for Amgen Inc. The lowest target is $195 and the highest is $405. Please note analyst price targets are not guaranteed and could be missed completely.

AMGN Analyst Ratings

About 32 Wall Street analysts have assignedAMGN 14 buy ratings, 16 hold ratings, and 2 sell ratings. This means that analysts expect Amgen Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMGN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

AMGN stock forecast by analyst

These are the latest 20 analyst ratings of AMGN.

Analyst/Firm

Rating

Price Target

Change

Date

Gregory Renza
RBC Capital

Outperform

$330

Maintains

Nov 27, 2024
Tim Anderson
Wolfe Research

Peer Perform


Initiates

Nov 15, 2024
Geoff Meacham
Citigroup

Neutral

$335

Initiates

Nov 14, 2024
Michael Yee
Jefferies

Buy

$380

Maintains

Nov 12, 2024
Colin Bristow
UBS

Neutral

$326

Maintains

Oct 31, 2024
Olivia Brayer
Cantor Fitzgerald

Overweight

$405

Reiterates

Oct 22, 2024
Yaron Weber
TD Cowen

Buy

$383

Maintains

Oct 21, 2024
Aaron Gal
Bernstein

Outperform

$380

Initiates

Oct 17, 2024
Robyn Karnauskas
Truist Securities

Hold

$333

Downgrade

Oct 14, 2024
Carter Gould
Barclays

Equal-Weight

$315

Maintains

Oct 7, 2024
Olivia Brayer
Cantor Fitzgerald

Overweight

$405

Initiates

Sep 27, 2024
Gregory Renza
RBC Capital

Outperform

$362

Reiterates

Sep 26, 2024
Brian Skorney
Baird

Underperform

$215

Reiterates

Sep 25, 2024
Gregory Renza
RBC Capital

Outperform

$362

Maintains

Aug 7, 2024
Mohit Bansal
Wells Fargo

Equal-Weight

$335

Downgrade

Aug 7, 2024
Jay Olson
Oppenheimer

Outperform

$380

Maintains

Aug 7, 2024
James Shin
Deutsche Bank

Hold

$305

Reiterates

Aug 7, 2024
Yaron Weber
TD Cowen

Buy

$381

Maintains

Aug 7, 2024
Geoff Meacham
B of A Securities

Neutral

$330

Maintains

Aug 7, 2024
Terence Flynn
Morgan Stanley

Equal-Weight

$303

Maintains

Jul 11, 2024

AMGN Company Information

What They Do: Biopharmaceutical company developing human therapeutics.

Business Model: The company discovers, develops, manufactures, and sells a range of human therapeutics primarily targeting chronic diseases and conditions. Amgen generates revenue by marketing its products to healthcare providers and directly to consumers, utilizing a distribution network that includes pharmaceutical wholesalers and clinics.

Other Information: Amgen's extensive product portfolio includes treatments for autoimmune diseases, cancer, osteoporosis, and other serious conditions. The company actively engages in collaboration agreements with major pharmaceutical firms to enhance its product offerings and expand its market reach. Founded in 1980 and based in Thousand Oaks, California, Amgen is a leader in the biotechnology sector.
AMGN
Amgen Inc (AMGN)

When did it IPO

1984

Staff Count

26,700

Country

United States

Sector/Industry

Healthcare/Drug Manufacturers - General

CEO

Mr. Robert A. Bradway

Market Cap

$146.52B

Amgen Inc (AMGN) Financial Data

In 2023, AMGN generated $28.19B in revenue, which was a increase of 7.09% from the previous year. This can be seen as a signal that AMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$25.42B

Revenue From 2021

$25.98B

2.18 %
From Previous Year

Revenue From 2022

$26.32B

1.32 %
From Previous Year

Revenue From 2023

$28.19B

7.09 %
From Previous Year
  • Revenue TTM $32.53B
  • Operating Margin TTM 24.2%
  • Gross profit TTM $19.74B
  • Return on assets TTM 4.6%
  • Return on equity TTM 55.7%
  • Profit Margin 13.0%
  • Book Value Per Share 14.00%
  • Market capitalisation $146.52B
  • Revenue for 2021 $25.98B
  • Revenue for 2022 $26.32B
  • Revenue for 2023 $28.19B
  • EPS this year (TTM) $7.82

Amgen Inc (AMGN) Latest News

News Image

Sat, 07 Dec 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Amgen's Phase 3 study shows that adding BLINCYTOยฎ to chemotherapy improves three-year disease-free survival to 96% in pediatric patients with standard risk B-cell ALL.

Why It Matters - Positive Phase 3 results for BLINCYTOยฎ suggest strong market potential and improved outcomes in pediatric cancer treatment, potentially boosting Amgen's revenue and stock performance.

News Image

Sat, 07 Dec 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - The "Dogs of the Dow" refers to the highest-yielding stocks in the Dow Jones Industrial Average. Investors should assess whether these stocks are undervalued or facing potential risks.

Why It Matters - The "Dogs of the Dow" strategy highlights high-yield stocks that may signal undervaluation or risk. Investors need to assess underlying reasons for price drops to make informed choices.

News Image

Mon, 09 Dec 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - Dividend-paying stocks can provide steady passive income and may help investors outperform the S&P 500 index.

Why It Matters - Dividend-paying stocks can provide consistent income and potentially outperform the S&P 500, appealing to income-focused investors and those seeking stability in their portfolios.

News Image

Thu, 05 Dec 2024

Sentiment - POSITIVE

Source - Reuters

Summary - Amgen will invest $1 billion to establish a second drug substance manufacturing facility in North Carolina, enhancing its production capabilities.

Why It Matters - Amgen's $1 billion investment in North Carolina signals growth and expansion, potentially boosting revenue and market position, which may positively impact stock performance.

News Image

Thu, 05 Dec 2024

Sentiment - POSITIVE

Source - CNBC

Summary - Amgen's weight loss injection, MariTde, is under scrutiny by Wall Street. Additionally, GE HealthCare plans to acquire a Japanese drug company.

Why It Matters - Amgen's weight loss injection could impact its revenue growth and market share, while GE HealthCare's acquisition may enhance its product portfolio and competitive positioning.

News Image

Thu, 05 Dec 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - When the Federal Reserve indicates monetary easing, investors typically favor stable, high-yield dividend stocks for income and growth potential.

Why It Matters - Rising interest rates often lead to a shift in investor preference towards dividend stocks, impacting their demand and prices, which can influence overall market dynamics.

...

AMGN Frequently asked questions

The highest forecasted price for AMGN is $405 from Olivia Brayer at Cantor Fitzgerald.

The lowest forecasted price for AMGN is $195 from from Jefferies

The AMGN analyst ratings consensus are 14 buy ratings, 16 hold ratings, and 2 sell ratings.